MOUNTAIN VIEW, Calif., May 15 /PRNewswire-FirstCall/ -- Alexza
Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that its corporate
presentation will be webcast live during the Seventh Annual JMP Securities
Research Conference on Monday, May 19, 2008 at 11:30 a.m. Eastern Time and at
the Citi Investment Research Global Healthcare Conference on Wednesday, May
21, 2008 at 2:00 p.m. Eastern Time.
The JMP presentation will be webcast from The Ritz-Carlton Hotel in San
Francisco. To access the live presentation via the Web, please go to the
Investor Relations tab at www.alexza.com or at
http://www.wsw.com/webcast/jmp6/alxa/.
The Citi Investment will be webcast from the Hilton New York Hotel in San
New York. To access the live presentation via the Web, please go to the
Investor Relations tab at http://www.alexza.com or at
http://www.veracast.com/webcasts/citigroup/healthcare08/31112361.cfm.
A replay of each webcast will be made available approximately 24 hours
after the live presentation and the replay will be archived for 14 days.
Alexza Pharmaceuticals is an emerging specialty pharmaceutical company
focused on the development and commercialization of novel, proprietary
products for the treatment of acute and intermittent conditions. The
Company's technology, the Staccato(R) system, vaporizes unformulated drug to
form a condensation aerosol that allows rapid systemic drug delivery through
deep lung inhalation. The drug is quickly absorbed through the lungs into the
bloodstream, providing speed of therapeutic onset that is comparable to
intravenous administration, but with greater ease, patient comfort and
convenience.
Alexza has six product candidates in clinical development. Alexza's lead
program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in
schizophrenic or bipolar disorder patients, is in Phase 3 testing. AZ-001
(Staccato prochlorperazine) for the acute treatment of migraine headaches has
completed Phase 2 testing. AZ-104 (Staccato loxapine) for the acute treatment
of migraine headaches and AZ-002 (Staccato alprazolam) for the acute treatment
of panic attacks associated with panic disorder are in Phase 2 testing.
Product candidates in Phase 1 testing include AZ-003 (Staccato fentanyl) for
the treatment of breakthrough pain, which is partnered with Endo
Pharmaceuticals in North America, and AZ-007 (Staccato zaleplon) for the
treatment of insomnia. More information, including this and past press
releases from Alexza is available online at http://www.alexza.com.
Safe Harbor Statement
The anticipated presentation will contain forward-looking statements that
involve significant risks and uncertainties. Any statement describing the
Company's expectations or beliefs is a forward-looking statement, as defined
in the Private Securities Litigation Reform Act of 1995, and should be
considered an at-risk statement. Such statements are subject to certain risks
and uncertainties, particularly those inherent in the process of developing
and commercializing drugs. The Company's forward-looking statements also
involve assumptions that, if they prove incorrect, would cause its results to
differ materially from those expressed or implied by such forward-looking
statements. These and other risks concerning Alexza's business are described
in additional detail in the Company's Annual Report on Form 10-K for the year
ended December 31, 2007, and the Company's other Periodic and Current Reports
filed with the Securities and Exchange Commission. Forward-looking statements
contained in this announcement are made as of this date, and the Company
undertakes no obligation to publicly update any forward-looking statement,
whether as a result of new information, future events or otherwise.
SOURCE Alexza Pharmaceuticals, Inc.
